As showed by relevant literature, this condition appears to be increasingly frequent after the introduction of sodium glucose-cotransporter 2 inhibitors (SGLT2i), a new class of drugs for the treatment of T2DM patients [1]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.